Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus

Table 4 Unadjusted sensitivity analysis of factors associated with serious adverse events

	OR	95%CI	P value
Demographics and clinical characteristics
Age, yr	0.99	0.91-1.08	0.79
Gender, female	2.73	0.54-18.42	0.28
Race, black	0.44	< 0.01-2.76	0.49
Ethnicity, Hispanic	0.26	< 0.01-2.37	0.39
Weight, lbs	0.97	0.94-0.99	0.02
BMI, kg/m2	0.85	0.69-1.02	0.08
Years since transplant	0.98	0.85-1.12	0.75
Comorbidities
Hepatocellular carcinoma	1.21	0.24-6.04	1.00
Diabetes	1.01	0.22-4.74	1.00
Hypertension	1.15	0.23-6.45	1.00
Depression	0.6	0.01-7.16	1.00
Liver disease severity
Cirrhosis	0.8	0.07-5.68	1.00
FIB-4	1.08	0.94-1.22	0.28
FIB-4, ≥ 3.25	0.99	0.20-5.55	1.00
Treatment naïve	1.33	0.18-8.56	1.00
Treatment Regimen
SOF/RBV	REF	REF	REF
SOF/PEG/RBV	0.91	0.12-3.46	1.00
Genotype
1	REF	REF	REF
2	8.47	0.30-744.15	0.31
3	2.27	0.16-31.69	0.72
4	3.03	0.04-256.92	0.90
Labs
Hemoglobin (g/dL)	0.63	0.36-0.95	0.02
(Ref: 13.9-16.3 g/dL)
Platelets (× 103/μL)	0.99	0.98-1.00	0.14
(Ref: 150-450 × 103/μL)
HCV viral load [log10 (IU/mL)]	1.03	0.41-2.60	0.95
(Ref: 15-108 IU/mL)
Serum creatinine (mg/dL)	2.02	0.81-5.91	0.14
(Ref: 0.70-1.40 mg/dL)
eGFR (mL/min per 1.73 m2)	0.95	0.91-0.99	0.03
Albumin (g/dL)	0.76	0.26-2.31	0.63
(Ref: 3.5-4.9 g/dL)
ALT (U/L)	0.99	0.98-1.00	0.43
(Ref: 1-53 U/L)
AST (U/L)	0.99	0.99-1.01	0.78
(Ref: 1-50 U/L)
INR	2.93	0.35-29.0	0.36
Total bilirubin (mg/dL)	1.94	1.05-4.69	0.02
(Ref: 0.1-1.2 mg/dL)
Alpha fetoprotein (ng/mL)	1.04	0.99-1.12	0.16
(Ref: 0.0-9.0 ng/mL)

BMI: Body mass index; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon; eGFR: Estimated glomerular filtration rate; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio.